Syngene International Limited (SYNGENE) Earnings Call Transcript & Summary
October 28, 2026
Earnings Call Speaker Segments
Executive
executiveGood morning, everyone, and thank you for joining this call, where we'll be discussing Syngene's second quarter results for FY 2027. With us today to talk about the financial and business performance for the period are Kiran Mazumdar-Shaw, Syngene's Executive Chairperson; Mr. Siddharth Mittal, Managing Director and Chief Executive Officer; and Mr. Deepak Jain, Chief Financial Officer. Once the opening remarks are done, they'll be glad to take any questions you might have. Before we get started, I'd like to note a caution: remarks made on today's conference call will include certain forward-looking statements, and these need to be viewed in light of the risks pertaining to the business. The safe harbor clause set out in the investor presentation likewise applies to this conference call. A recording and transcript of this call will be posted on the company website; with that, I'll now hand the call over to our Executive Chairperson, Mr. Kiran Mazumdar-Shaw.
Kiran Shaw
executiveThanks, Soudabi. Morning, all — glad you could be with us. At the close of the quarter — last quarter, I described FY '27 as a time of transition and transformation for Syngene, one where we could reset our growth priorities, sharpen our competitive edge and lay a stronger foundation for sustainable, profitable growth. I set out three strategic priorities: reenergizing our commercial engine, making CDMO our principal growth driver and transforming Discovery Services into a more differentiated, technology-enabled and higher-value business. Our second quarter results give encouraging early signs that this strategy is beginning to gain traction. As many of you are aware, the global pharmaceutical industry is undergoing a significant transformation. Pharma and biotech firms are rethinking how they do research, development and manufacturing, driven by growing scientific complexity, new therapeutic modalities, mounting cost pressures and the need for resilient global supply chains. Customers increasingly seek strategic partners that can bring together scientific excellence, technological sophistication and manufacturing capabilities in one integrated operating model — and that shift plays directly into Syngene's strength. On top of this, of course, come today's geopolitical realities, which likewise favor companies such as Syngene under a China Plus One model. CDMO sits at the heart of this ambition. We see CDMO as Syngene's biggest long-term growth opportunity, especially as the industry moves toward biologics of rising complexity, advanced modalities and more diversified manufacturing networks. We think the money we've put into biologic drug production in India and America, along with our growing know-how in peptides, oligonucleotides and other niche technologies, means we're in a strong position to seize these new chances. One standout moment during the quarter came when we signed our very first production deal for the Bayview Biologics site in America; that goes beyond simply landing business — it confirms the value of our combined India-U.S. biologics production approach, pairing India's scientific talent and operational muscle with a manufacturing base in America so clients gain more options and a sturdier supply chain. Although it will take time for these investments to reach their full commercial potential, we're encouraged by stronger customer engagement and a larger opportunity pipeline. Our second strategic priority is repositioning Discovery Services for the coming era of innovation. Tomorrow's drug discovery will be defined by biology, chemistry, artificial intelligence, automation and data-driven science coming together; we believe Syngene possesses the scientific depth, multidisciplinary expertise and experimental infrastructure needed to take a meaningful part in this transformation. What we're investing in peptides, antibody drug conjugates, translational sciences and other advanced capabilities is enhancing our capacity to support discovery programs of growing complexity. Alongside that, we're bringing AI, automation, and digital tech into our scientific workflows to boost productivity, cut development timelines, and improve both the quality and pace of decisions. Our goal is to shift Discovery Services away from a model driven mainly by execution and toward a scientific solutions platform that's more integrated and intelligence-driven. This transition will take a while, but it's hugely important if we want an operating model for the future that stands out more and competes better. So we're heading toward an operating model that's more agile, more efficient, and more accountable, keeping a sharp eye on cost competitiveness, on how well we use capacity, and, of course, on returns on invested capital. It's encouraging that revenue and profitability improved sequentially this quarter, which hints that the corrective steps we've taken are starting to produce results; even so, we fully acknowledge these are green shoots. There's still more work ahead of us if we're to bring back consistent growth, strengthen operating leverage and capture the full potential of the investments we've made. Converting a commercial pipeline that is improving into revenue growth that lasts is our immediate priority, and we'll do that while keeping execution and cost discipline strict. I have confidence that Siddharth and the leadership team around him possess the right strategic focus and the operational commitment needed to deliver this transformation. To my mind, Syngene's reputation rests on scientific excellence, quality, and customer trust. Our task now is to leverage those strengths toward an organization that is more technology-driven, globally competitive, and profitable—simply restoring growth is not our goal. We are repositioning Syngene for the coming era of scientific innovation and global biopharmaceutical manufacturing. With that, I'll pass things to Siddharth, who will walk through the quarter in detail. Siddharth, over to you.
Siddharth Mittal
executiveThank you, Kiran, and a very good morning to all of you. As Kiran laid out, FY '27 represents a transitional year for Syngene, with a sharp focus on bringing back growth momentum, tightening up execution and enhancing operating efficiency. Early in the year we set out three immediate priorities: speeding up commercial execution, lifting operational performance, and creating an organization that is leaner, more agile and more cost competitive. During the second quarter, we achieved tangible progress across all three of those fronts. Revenue rose 13% sequentially. Operating EBITDA margins gained 6 percentage points, and we returned to profitability. Although we are still trailing last year's performance, these results show that our corrective actions are starting to produce better business outcomes. Let me walk through the key developments in the quarter. Our CDMO business remains a central focus of our commercial strategy, and we are encouraged by the improving quality and momentum in our opportunity pipeline. A major milestone this quarter was signing our first manufacturing agreement for the Bayview Biologics facility in the United States with a large pharmaceutical customer. Under this agreement, process development activities are expected to begin in India during the current financial year, with drug substance manufacturing at Bayview set to start in FY '28; this contract marks an important first step in commercializing our U.S. biologics manufacturing platform and shows the strategic value of our integrated India-U.S. delivery model; we secured additional manufacturing business during the quarter, including a clinical supply agreement for our biologics manufacturing facility in Bangalore, Unit 3. That is the latest in a series of contracts with an existing partner and reflects continued customer confidence in our scientific capabilities, manufacturing quality and execution. We also successfully completed a technically complex oligonucleotide manufacturing program for a leading global pharmaceutical company. The program involved developing and manufacturing a challenging siRNA molecule, demonstrating our capabilities in process development, optimization and scale-up for advanced therapeutic modalities. These developments reinforce our strategy of building a diversified CDMO platform able to support increasingly complex molecules across clinical and commercial stages. Turning to Discovery Services. Our focus is on creating an offering that is more integrated, differentiated and productivity-driven. Effective October 1, 2026, Dr. Jayashree Aiyar, our Chief Scientific Officer, took on additional responsibility for Discovery Services, bringing chemistry, biology and biotherapeutics under unified scientific leadership. This is an important organizational step: by integrating these disciplines, we aim to strengthen scientific collaborations, improve program execution and give customers a more seamless discovery experience. As drug discovery becomes increasingly multidisciplinary, our ability to integrate scientific capabilities across modalities will be an important competitive differentiator. Our Discovery Services customer base stayed stable during the quarter, providing a foundation as we strengthen our commercial engagement and work towards restoring growth. We are also speeding up the deployment of AI, automation and digital technologies across research operations. During the quarter, we implemented ChemVoyager, an AI-enabled synthesis planning platform, alongside automated analytical systems and end-to-end sample tracking solutions. The aim behind these efforts is to build scientific workflows that are more connected and driven by data, to cut down on manual interventions and to boost research productivity. As time goes on, we anticipate that such technologies will strengthen our capacity to provide customers with research solutions that are quicker, more effective and of greater value. In addition, we set up a new clinical translational science laboratory in Bangalore, which extends what we can do in biomarkers, precision medicine, biobanking and bioanalysis. Through this investment, our translational research capabilities are reinforced and our capacity grows to link early discovery with clinical development. It further fits with our goal of making discovery services more scientifically differentiated, more enabled by technology and more commercially competitive. Before I move on to our financial performance, I want to share a significant leadership update as well. Deepak Jain, who serves as our CFO, has chosen to depart from Syngene for personal reasons and will take up an opportunity elsewhere. Deepak will stay in his present position at least through the close of third quarter's financial results, so that his responsibilities can transition smoothly and continuity is assured. We are grateful to Deepak for what he has contributed and wish him well in his future endeavors; now moving on to financial performance. Revenue from operations in the second quarter came to INR 833 crores, a 13% rise sequentially, helped by stronger traction in the CDMO business; compared with a year earlier, revenue was 9% below quarter 2 of the prior fiscal year, mainly because Zoetis revenue was absent this quarter. Discovery Services made up 65% of quarterly revenue, and CDMO represented the remaining 35%. Operating EBITDA came in at INR 147 crores, with margins sequentially better by 6 percentage points at 18%; that gain came from higher revenues, better operating leverage and the first benefits of our cost optimization initiatives. Against the prior year, operating EBITDA margin was 22% lower than what was reported in Q2 of last year, reflecting, of course, reduced revenues from Librela and a foreign exchange hedge loss of INR 61 crore that we recorded during the quarter. If that hedge loss were adjusted for, operating EBITDA margin for the quarter would be in the mid-20 range. Profit after tax, but before exceptional item, was INR 38 crore. We recorded an exceptional charge of INR 6 crores net of tax tied to employee termination benefits, which brought reported profit after tax to INR 32 crore. That compares with a reported loss of INR 9 crores in the prior quarter, an encouraging return to profitability. Now, in parallel with commercial recovery, we are carrying out structural improvements aimed at strengthening our cost competitiveness and operating efficiency. Our manpower cost optimization measures are finished, while initiatives focused on other operating expenses are still in progress. We anticipate that the benefit from these actions will show up increasingly over the quarters ahead. We are also expanding the use of AI automation and digital technologies throughout our operations, so that productivity improves, workflows are simplified and execution is strengthened. What we're focused on isn't just cutting costs. It's about creating a more efficient operating model capable of delivering better margins and improved returns once revenue growth comes back. In the first half, capital investment came to roughly INR 200 crore, going toward strategic capability development, Bayview enhancements, automation and infrastructure upgrades across our research and CDMO business. We stay disciplined when it comes to capital allocation, putting priority on investments that bolster our competitive position, back customer demand and enhance long-term returns. Our balance sheet is still strong, with a net cash position of INR 1,392 crore at quarter end, which gives us financial flexibility to support our transformation and growth priorities. For Syngene, the second quarter is an encouraging step forward in its recovery. Commercial engagement has been stronger, we've secured important manufacturing contracts, operating performance has improved and we've made tangible progress on our efficiency initiatives. That said, we do recognize that a single quarter of sequential improvement doesn't amount to a sustained recovery. So for the second half our focus stays clear: turning our commercial pipeline into business wins, delivering consistently on quality and time lines, improving capacity utilizations and embedding greater cost discipline throughout the organization. As we work toward building a more resilient and competitive business, we'll keep prioritizing growth, operational excellence and disciplined capital deployment. Results from the actions taken over the past two quarters are starting to appear. What we need to do now is sustain this momentum and translate it into consistent performance. And Syngene is shifting from a period of transition toward a more focused, technology-enabled and globally integrated business model. The early signs of recovery are encouraging, but sustained revenue growth, stronger profitability and improved returns on capital will be our real measure of success. So with that, we'd be happy to take your questions. Thank you.
Kunal Dhamesha
analystKunal here from Macquarie. Congrats on a solid set of numbers. First question is for Kiran ma'am; we've noticed quite a bit of turnover among senior management during this quarter as well. Would you say the internal reorganization is complete at this point, or will we keep taking steps to make the organization more efficient?
Kiran Shaw
executiveWell, Kunal, thank you for your question. I believe most of the reorganization is now in a good place. I'd say we will onboard some other capabilities that we believe matter for driving us to the future. But I think most of the reorganization we had anticipated and planned is complete.
Kunal Dhamesha
analystSure. If my memory serves me right, during the previous quarter we experienced a certain amount of attrition within the client base of our Discovery segment, correct? So would it be reasonable to think that — and at that time we had indicated that we were sort of stepping away from the low-value services. Is it reasonable to think this reorganization push is likewise headed in those directions where the business requirements sit and where the business — certain business segments we don't wish to pursue?
Kiran Shaw
executiveThat's exactly right. I believe we are extremely, extremely focused on ensuring we offer a differentiated services model. The commoditizing services that carry very, very low margin or no margin at all are the kind of thing we want to wean ourselves away from. And so I think we are truly concentrating on a highly differentiated model. As you're aware, we are already highly differentiated in the biologics model as far as the CDMO business goes, which explains why we're starting to witness solid traction in signing up our capacities, since nobody else holds such capacities, particularly capacities approved by the U.S. FDA. So I think we are very focused on making sure that we, once again, regain our standing as a leading edge CRO, CDMO company.
Siddharth Mittal
executiveAnd let me add to that, Kunal, we aren’t discontinuing any existing business on Discovery. So what we’re doing is repositioning, and as we said, we’ll be using a lot of AI automation and digital technologies, especially on the new modalities, and trying to integrate our offerings across discovery services. Discovery will remain a very core part of our overall journey, but we’ll redo the way we have — traditionally, it’s been more of an FTE business. What we’re looking at is embedding AI to make it more of a fee-for-service value-add business.
Kunal Dhamesha
analystSo that's a key difference, isn't it—shifting from one business model to another, or a mix shift happening. Which monitorables would matter most to you as you track this? Because I do think that given the lumpiness in the CMO business, financial performance might come through a bit uneven or volatile. Still, which metrics would you point to that ought to show steady quarter-on-quarter improvement, with all the efforts you're making and the reorganization underway?
Siddharth Mittal
executiveLook, new client additions, how many new projects we bring on board, how many molecules we move from discovery into development—those will matter. And in the end, it's all—it should all show up as revenue growth. I mean, we've watched the Discovery business decline versus the prior year and the prior quarter, owing to some client attritions we had early in the first half, I think, which we mentioned on our first quarter earnings call. And naturally, we'll focus on rebuilding the base, though in a differentiated manner. As I said, in an integrated manner, since today Discovery Biology and Discovery Chemistry operate as two separate OUs. And now, I mean, we're going to bring that together into a single offering, and that's what our customers are looking at; so when you really examine what our customers need, we have to be agile enough to meet those needs; so we—as we said, it won't be an overnight turnaround. We will have—we have begun to see an encouraging client pipeline, encouraging client discussions. But for that to translate into revenue growth, we'll need a bit more time.
Kunal Dhamesha
analystCertainly. So if you shift, say, from an FTE basis over to FFS, how does that affect productivity and profitability structurally within the Discovery business?
Siddharth Mittal
executiveIt should...
Kiran Shaw
executiveYeah, I'd say it ought to be quite favorable, since our view is that value will come from it. And my sense is that this will essentially let us land considerably stronger programs from clients.
Kunal Dhamesha
analystAnd historically, we would have witnessed this, correct?
Kiran Shaw
executiveNo, we're already seeing it, thanks to the differentiated services we offer as well; and I believe incorporating some technology into it, and then more technology further down the line, will obviously give us a leading edge.
Kunal Dhamesha
analystAlright, my final question concerns this Bayview facility contract we've secured. With that contract in hand, what level of utilization do we expect for the facility? And at what point do you expect peak utilization for drug substance manufacturing to arrive? Also, regarding the Unit 3 contract with the current partner — is that the same partner we previously had the CMO arrangement with?
Kiran Shaw
executiveKunal, allow me to share my perspective on that first. Above all, as you're aware, our focus is on capacity utilization across all our facilities, but Bayview is a site that essentially has to be brought up to scale, since we have identified certain gaps that must be fixed before full utilization is reached. What's encouraging is that we've signed this initial contract, which clearly then must be built upon. I think this is — as we stated quite clearly in both of our statements, this isn't merely about signaling that we've arrived and done everything required. It's simply an indication that this win signals how important having a U.S. presence is and the confidence customers have to sign up. I'd go as far as saying demand for biologic manufacturing capacity is enormous. And I think at present, those capturing that opportunity are the Koreans; we'd like to be the Indian company of choice, the Indian CRDMO of choice, to really take advantage of this demand; so give us a bit of time. I think the fact that we've begun focusing on identifying what we need to do to really ensure optimal capacity and a very strong business growth driver from CRDMO is exactly what we're addressing.
Kunal Dhamesha
analystCertainly, ma'am. What about the Unit 3 contract with the existing partner?
Siddharth Mittal
executiveWe have multiple customers signed up for Unit 3; a few are running clinical batches, a few are running development batches, and a few are running filing batches. And naturally, ramping up will take time again, which depends on when they receive approval from the regulators; but at least Unit 3 has a solid group of clients signed on.
Harith Mohammed
analystHarith here, calling from Avendus. My first question concerns your FY '27 margin guidance. Last quarter, I believe you kept it at mid-20s. Yet the margins implied for the second half represent a steep gain versus what we delivered in the first half. So my first question is: are we still holding to that same mid-20s EBITDA margin guidance? And one related point, if I may add it, is that we've also seen a fairly sizeable forex loss across the last couple of quarters. So if the rupee remains where it is now, do we expect a similar forex loss in the third quarter and the fourth quarter?
Siddharth Mittal
executiveHarith, the EBITDA guidance is unchanged. As you correctly noted, we have done better. At mid-20 EBITDA, we exclude the forex loss. We keep working on cost optimization benefits; some further benefits should come through in the second half. But at this point, we would prefer to hold our EBITDA guidance. As for the forex loss, we do have contracts, forward contracts, on one of our large dedicated customer contracts, which runs until FY '28. So we will see a similar level of hedge losses in the second half as well.
Harith Mohammed
analystAll right. For my second question, I want to ask about the Bayview facility. Siddharth, could you verify the contract you announced? You also said drug substance supplies will begin next year. Will those be commercial-scale supplies? And is this a product already on the market?
Siddharth Mittal
executiveYes, it will be for commercial supplies too. As I said earlier, the product's development will happen in the Indian process development lab, and it will be tech transferred to Bayview in FY '28. Once the regulators give approval, we will serve as their commercial manufacturing partner. And of course — I mean, at present the product is not commercially approved. So that is why we must wait for the regulators to approve the product and start the commercial supplies in a couple of years.
Harith Mohammed
analystAnd a quick follow-up regarding Bayview. Those pre-op costs we're capitalizing right now — I believe you disclosed a figure of INR 66 crore for the first half. So when should we expect that to begin showing up in the P&L?
Siddharth Mittal
executiveOnce we — I mean, under our accounting policy, we capitalize those expenses up to the point we get the first regulatory approval, which we're expecting somewhere around maybe the second half of calendar '28, best case.
Shyam Srinivasan
analystThis is Shyam calling from Goldman Sachs. My first question is about the mix. Siddharth, if I did the math on the 65% Discovery and 35% CDMO split you mentioned, right? So when I work that through — and I believe you hinted at this too, that the Discovery business, the CRO business, has now fallen for two quarters. And it seems at least the CDMO business, when you said in your opening remarks that Librela was absent, well, that hasn't declined. It's only down a bit over 3% Y-o-Y, correct? So the weaker Discovery side is really what drives the Y-o-Y change. Do I have that right?
Siddharth Mittal
executiveWell, Shyam, it's both things combined, because last year in quarter 2 we had a significant number for supplies to Zoetis. This quarter that figure has been 0, so that certainly had an impact, though growth in the rest of the CDMO business offset it. But yes, the Discovery business did degrow.
Shyam Srinivasan
analystUnderstood; and you'd mostly put that down to the… it began right at the outset, correct? What kind of customers are these, exactly? And is it the case that we've pulled back on certain commoditized portions of the segment, and that explains the decline; and do you expect this to continue into the second half too, Siddharth?
Siddharth Mittal
executiveWell, as I believe we noted both on last quarter's call and on today's call, a number of these services are turning more commoditized, with competitive pressure coming from big CROs in China and also from some newer CROs in India. We aren't engaging in a price game or a price-per-FTE game; and that, I think, is precisely why we're working to become a more integrated, AI technology-led business and to shift away from FTE toward FFS, which naturally will need some time for the transition out and the move into the newer model.
Kiran Shaw
executiveAnd there's something I'd like to add to Siddharth's point, Shyam, which is that a portion of the business attrition really comes from the big cuts those companies are announcing themselves when it comes to reducing their R&D spending. So that effect is showing up for us.
Siddharth Mittal
executiveAnd I think if you look at the traditionally large biotech pharma companies in the West, a lot of discovery work has been done by them in-house, whether in their own labs or through CROs. And now, if you look, 1/3 of the total number of drugs under trial at different stages of trial come from China in in-licensed models. So that is, of course, changing the need for discovery services, which is, of course, going to impact all the CROs.
Shyam Srinivasan
analystAll right, that's useful. My second question concerns the financial side. Gross margins did in fact get better, correct, even though discovery fell and CDMO also went down. So I'm only trying to work out whether taking out the commoditized portion is what's driving the improvement we see in gross margin. That's the first thing. And second, now that you're keeping your EBITDA margin guidance as it is, does that leave out all the FX losses? Because if the FX losses are added in, we might not land at mid-20, right? Is that a fair way to put it?
Siddharth Mittal
executiveLook, gross margin gets calculated, I believe, as revenue minus material cost, and material cost, naturally, applies only in the manufacturing business... in the CDMO business. Research, by contrast, carries more people cost plus leases and other items, and those tend to be more fixed in nature. So that's the reason I shouldn't — I don't believe you really ought to compare gross margin movement, given the shift of revenues from discovery into development. Still, on an absolute basis within the CDMO business, I'd say our gross margins sit at roughly similar levels. Naturally, Zoetis or Librela was a high-margin product, and its absence did affect things by lowering gross margin, at least for that portion of the business; and regarding the EBITDA guidance, I think, look, I'd say let's hold off for another quarter. We are, naturally, making every effort on cost optimization. We've already accomplished a good deal over the last two quarters; we've begun to see benefits arrive. We're also examining where the growth is coming from. And naturally, discovery and development business arrives at different margins. But at this point, I'd have to say there is a significant change in our — EBITDA guidance; yet on a more sustainable basis, I think I would certainly point out to you that on hedge losses, we have altered our hedge policy, and we will begin shifting toward options more than forward contracts. And once the present hedges run their course, which happens in FY '28, the sustainable level of gross margins, we are already in mid-20s. And I think that's the crucial point.
Surya Patra
analystMy first question concerns the SG&A cost improvement we saw this quarter. It looks like, well, we've arrived at a level that was the normalized kind of spend before the possibly difficult stretch of the last 1.5 years or so. So how sustainable is that cost — the SG&A run rate — going forward? And are we truly seeing the payoff from the cost optimization initiative we've undertaken, and hence it's likely to hold up even ahead, and that will support the margin profile going forward? Any thoughts on that, sir?
Siddharth Mittal
executiveThat will be our endeavor, Surya, to keep the expenses at these levels; and as we mentioned, some of the cost initiatives we have undertaken, we will see, in fact, additional benefits coming in, in the second half.
Surya Patra
analystYes, sir. The second question concerned discovery services; so sir, if you could tell us something about capacity utilization there, or what headroom exists on the discovery research side, since that has been a growth driver through all the difficult times. So I'm just trying to understand, while the investments have gone toward the CDMO side, how sustainable is the growth momentum we can have on the discovery front? And what investment is planned for that, if you could speak to it?
Siddharth Mittal
executiveLook, our labs are already in place, and given the client attrition we've seen, we have sufficient capacity to bring on more customers. Our bench strength can support the growth. But we will be investing, as I mentioned earlier, on two fronts. First, infrastructure upgrades to align with what our customers are seeking, and second, AI automation and digitalization. I mean, some of the investments in automation and digitization are going to be high; and we are evaluating which solutions are the best possible ones and at what scale we should add, and we will make those investments over the coming quarters.
Surya Patra
analystAll right, all right. Sir, just to follow up on that point — as an extension, so to speak. This new clinical translation science lab that you brought up: how should we interpret this move, or what kind of significance can we draw from it for our revenue streams? And what sort of investment would you have put in here?
Siddharth Mittal
executiveLook, at bottom, this investment bolsters our translational research capabilities and boosts our capacity to link early discovery with clinical development. I think these days — I mean, Syngene stands among the few organizations offering fee to development to clinical to commercial across modalities, on both the small molecule and large molecule sides; and I think, as I said earlier, a great deal of translational data is needed during clinical development. And this lab will, naturally, matter; it will, naturally, be scientifically differentiated; it is technologically enabled and a very — a good lab, and many customers are keen to go to a single CRO or CRDMO rather than fragmenting various services across different partners; and I think that is exactly what Syngene can offer to customers. And on the investment side, I mean, it's — I don't have the figure at hand right now, but it isn't a very, very large investment.
Analyst
analystSajal Kapoor here, from Antifragile Thinking. Kiran ma'am and Siddharth, regarding the organic pipeline, what has to change so that programs which come in via discovery or early development remain with Syngene past a successful Phase II and on into Phase III and commercial supply?
Siddharth Mittal
executiveWell, Sajal, customers differ. I mean, some customers look to CROs or CRDMOs just for a particular need of theirs, or where a gap exists; typically those are the large biotech companies. And now we're also seeing at least some of the large biotech companies who are ready to move from the discovery stage to development. And certain companies that begin development work with us and later want commercial manufacturing done by us might not be end-to-end. But a large segment of customers exists, particularly small and mid-biotech customers, who don't want to go to separate partner service providers, and they want a single integrated partner, since that is the only way they'll get faster speed, skin in the game, better ownership and outcomes, because they also understand the CRDMO is fully vested in their success. And those are the customers we'll be chasing, where the molecule or the program enters at the discovery stage and we advance them through the different phases of development until commercial manufacturing. And we're already seeing some of these customers where we've signed up and we're making good progress with them. But we, of course, our commercial team will have to showcase this — the capabilities, end-to-end capabilities, together with our scientific teams; and we're very confident that over a period of time, we'll be able to add many more such programs in our portfolio.
Kiran Shaw
executiveThere's one more key thing I want to mention, Sajal, and that's this: anyone who is considering a CRDMO partner is after scale, right? They aren't interested in smaller companies that undercut on price yet only have limited facilities. What everybody wants is big capacity and big facilities, since they understand that the CRDMO business depends on serving multiple clients across multiple production sites and slots that they can then plug into. So that's precisely where I believe Syngene stands far apart from the rest on biological capacity — and at this point, naturally, we're also focused on reinforcing our small molecule capacity; but I want you to see that this is the area where we are strongly differentiated as a CRDMO coming out of India, because as you're aware, what the market wants is biologics capabilities. And the fact that we possess biologics capabilities spanning everything from discovery through to manufacturing, I believe, places us in a very strong and distinct category. So even on biologics capabilities, I think we hold a great many proprietary platforms that are now being presented to customers, thanks to a — significant push toward building a very robust commercial engine, which frankly, I'd say, carried quite a few gaps previously; and taking all of that together, I think you'll begin to witness solid traction over the upcoming quarters and the years ahead.
Analyst
analystNo, definitely, Kiran ma'am. I can't say whether any other Indian bio CDMO company is in a position right now to say it has 50 KL of ready capacity, and that is exactly what makes...
Kiran Shaw
executiveAnd the majority of Indian companies that play in this field will have only microbial fermentation, and not biologic fermentation.
Analyst
analystRight, not a mammal at all. For sure, definitely.
Siddharth Mittal
executivePlus the BIOSECURE Act genuinely brings a great deal of benefit.
Kiran Shaw
executiveWe are seeing a dual growing demand, I can tell you that.
Siddharth Mittal
executiveWe also provide a dual manufacturing approach, and a lot of CMOs aren’t able to do that — for example, even Samsung lacks a facility in the U.S. Right now, many customers, driven by geopolitical reasons and tariffs, MSNs want to make products in the U.S. for the U.S. market, and make them outside the U.S. for the rest of the world, and we provide that dual flexibility, that dual-site flexibility, with one tech transfer effort. The price is very competitive. I think I should also note that our pricing is very, very competitive versus either CMOs in the West or CMOs in the Far East.
Kiran Shaw
executiveAnd there's one more benefit: companies are interested in coming to India, getting the work done there, and then transferring the technology to the U.S. at our Bayview facility. So that's yet another model that's starting to emerge.
Analyst
analystNo question about it — Kiran ma'am, Siddharth, we see some thrilling periods coming up; and my next question is about capacity as such. On the Biocon Park Biologics site that ran the Zoetis program, which kinds of programs are we planning to occupy that capacity with, since it should be available for new work by now? And how ought we to frame the timing for when those commercial shipments take over from the former Librela production?
Siddharth Mittal
executiveSajal, across this latter half of the year, that site is going to be occupied, because we'll be producing batches for Zoetis and delivering them during the fourth quarter. We're in conversations with customers and giving them a look at all three of our biologics facilities. This particular site carries U.S. FDA approval, which naturally gives it an edge. That said, we won't be able to produce for any additional customer before the next fiscal year. So customers will pick whichever facility suits their requirements and schedules. As for how utilization builds across those three locations, we'll share more details when the time is right.
Analyst
analystSo Siddharth, just to be clear on this, it looks like there's still a bit of a tail remaining before the Librela contract wraps up, and after that the capacity frees up for a new customer, is that right?
Siddharth Mittal
executiveExactly. As we mentioned, there's an obligation to keep supplying Zoetis through this fiscal year too, and that will be weighted toward the back end, in the fourth quarter.
Analyst
analystThis is Prolin calling from Edelweiss Public Alternative. Kiran, I only have a single question for you, okay? Quite a few senior-level shifts have occurred, a few of them at the scientific and clinical level; so, given all these changes, when you think about the morale within the organization, how do you — what would — how would you compare that morale against, say, several years ago when things were going well for us, or when we launched Syngene as a Biocon subsidiary. Considering that our assets are largely people assets, correct, and scientists. With all these shifts taking place, these individuals also harbor concerns regarding what lies ahead; so in what way are we sustaining spirits and the culture inside the company amid so many changes at the senior level, encompassing the clinical and scientific tiers too?
Kiran Shaw
executiveLet me respond to that by noting that any company must accept the hard choice and act in the organization's best interest. Luckily, Syngene possesses a remarkably strong bench of talent, and our scientific talent at that level is exceptionally strong. Clearly, some disruption is inevitable when you implement changes this drastic, since the organization required rightsizing—it had genuinely become quite inefficient. So whenever you make these kinds of surgical decisions, a certain amount of worry, gossip, and even fear-mongering from departing employees is bound to surface. We're tackling that with a robust communications strategy, essentially telling everyone still here that they have no reason for concern. What this is really about is rebuilding the organization now. What I can say is that a significant amount of what I'd call additional expense came about because certain individuals had no assigned duties or responsibilities. That forced us to make those choices, and I believe from this point forward you'll see a far more unified, integrated operating model, which simply wasn't the case before. When an organization carries far too many staff, the tendency is toward silos and toward defending one's own turf. That's precisely what we're now working to rebuild — turning it into a cohesive organization. So we're addressing it, and I think it will deliver strong results. Those results will become apparent over the following two quarters, so this isn’t something we see as a major worry. Biocon, along with the wider Biocon Group and Syngene—which belongs to it—has consistently operated as a highly fair company; we place real value on our people, ensure they are treated with respect and given empowerment, and provide them with the strongest opportunities available.
Analyst
analystSure. Glad to hear that, ma'am. My second question concerns the CDMO model we're shifting, correct, from FTE to FTS, right? So ...
Kiran Shaw
executiveThe CDMO model is a different thing. Under the services model, it goes from FTE to FFS.
Analyst
analystYes. Sorry — I mean the services model. And you also said this change will need more time before results show up, correct? So is that extra time coming more from our side, in terms of capability, or is it more about clients testing us and running their own checks? What — what is it that's causing the longer timeline for this shift in the model on the services side?
Kiran Shaw
executiveSo I think we need to reposition ourselves with our customers, who have always viewed us through an FTE lens, and they're now starting to say, look — don't see us as an FTE model; we're an FFS model, thanks to our very deep scientific capabilities. It's starting to actually deliver results. But as I mentioned, it's very early days. So I don't want to get ahead of ourselves; what we're saying is I think this is how we will position Syngene. This is how we'll grow our business. And I think we're really concentrating on some of these high-end capabilities, because Syngene has always excelled in leading-edge capabilities ahead of others. We've identified several of these very strong capabilities ahead of others. And we will now reposition ourselves as the go-to CRO for these kinds of initiatives, and we're seeing huge demand for it.
Siddharth Mittal
executiveAdditionally, bringing in tech improvements plus upgrades around AI and automation is going to require time. That is the area, then, where we see something that sets us apart.
Kunal Randeria
analystEarlier this year, you announced that the Bristol Myers agreement was being expanded, and I take that as confirmation of the end-to-end offerings you provide. So could you maybe tell us what extra work you're now doing with them that you weren't doing before? And has that already begun to bring in revenue?
Kiran Shaw
executiveThe only thing we can say is that we're handling some interesting additional work for them, but confidentiality prevents us from sharing it.
Siddharth Mittal
executiveIncluding the development and the clinical work.
Kunal Randeria
analystRight, but does that cover manufacturing as well?
Siddharth Mittal
executiveYes, it does. Yes.
Kunal Randeria
analystRight, right. Okay. Perfect. Second thing — sorry, but that shift from FTE to FFS didn't quite land for me; so is it because, say, a particular scientist has paid — you're bidding it at $100,000 a year now.
Kiran Shaw
executiveI wish.
Kunal Randeria
analystNo, I’m only giving an illustration, ma’am. So suppose you do it, but now maybe thanks to better investments, your productivity has risen. And in order to capture that benefit, you’re shifting to FFS. Would that be the main reason for the move?
Kiran Shaw
executiveLet me respond to that, and Siddharth can chime in. The trouble is that when you go with an FTE model, whatever figure you quote, a competitor will come in lower and win the business, since it’s a commodity offering. That’s not the route we want to take. We want to take the route of value-added services, which means we’d prefer to go with fee for service, which, exactly as you say, if you can get $100,000 per scientist by doing so instead of going to a pristine model that is far lower than that, it works in your favor, because then clearly you do more for less and you get more for less.
Siddharth Mittal
executiveAnd let me add something here. Today, when you look at Indian CROs, their FTE charge-out rates run 30% to 40% below China's, and roughly half those of European or U.S. CROs. That said, I don't believe customers truly treat the per-FTE rate as the meaningful yardstick. What matters most to them, I think, is how long it takes to move a drug from discovery through to an IND filing or into the clinic, and what the total budget for that molecule will be through the IND filing. So even though your FTE rate might be lower or higher, the real science lies in how many FTEs you deploy, because when you apply technology, AI and automation to cut the FTE count, customers will pay a premium for that. And that is exactly the model shift we are describing.
Kunal Randeria
analystGot it. And if there's room, one more from me. Siddharth, you said your pricing is very competitive against both Western and Eastern companies, but how does it stack up against some Indian peers?
Siddharth Mittal
executiveWell, in large molecule CMO, there's barely any credible Indian player. I'm not referring to small molecule, of course, but our focus is heavily on biologic manufacturing. And beyond Syngene, which other Indian CMOs exist on the biologic side?
Kunal Randeria
analystRight, right. Okay, so you were referring to the biologic side rather than the small molecule side.
Siddharth Mittal
executiveOn small molecule, plenty of other Indian CMOs are either more competitive on cost or have significantly bigger capacity. That is the reason our emphasis there is on new modalities like peptides and oligonucleotides. I believe I said that we have completed highly, highly complex oligonucleotide manufacturing at a GMP level for one of our customers, ADC conjugation; we are the sole company that is fully integrated all the way from a biologic through linker and payload to conjugation at commercial scale.
Kiran Shaw
executiveOne point I really want to make is that, when you look at CROs and CRDMOs, some due diligence is needed on the investments they've made, the scale they've built, and their capability base, because I think everybody is only focused on quarter-on-quarter performance of small, slow-growing base businesses, and you have to ask whether they have put money into building scale.
Operator
operatorAlright, everyone, we'll treat that as the final question for today. Members of the management, thank you. That brings this conference to a close on behalf of Syngene International; we appreciate your participation, and you're welcome to leave the meeting at this point. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Syngene International Limited transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Syngene International Limited earnings transcripts and 131,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Syngene International Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.